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Coronary Artery Bypass Graft surgery 
(CABG) has an important value in the management 
of patients with coronary or valvular heart disease. 
Because of increasing the interest to perform less 
invasive interventions in these patients, CABG is 
now performed for patients with higher comorbidities 
and more severe cases having more post operative 
complications (1). Thus, clinical risk stratification 
has a great role in preoperative evaluation of patients 
undergoing CABG (2). Electrocardiography, 
hemodynamic parameters, biochemical markers like 
creatinin kinase (CK), myoglobulin creatinin kinase 
(CK-MB) and troponins and transthoracic/ 
transesophageal echocardiography are routinely used 
for the diagnosis of preoperative cardiac problems 
and prediction of perioperative comorbidities (3). 
BNP is secreted by ventricular myocytes due to 
increased ventricular wall tension related to volume 
expansion. BNP is a simple blood test, which can 
easily be performed in most biochemistry 
laboratories as part of a routine preoperative 
assessment. Previous studies showed that increased 
level of preoperative BNP is associated with higher 
morbidities and mortality after cardiac surgeries (4-
6). Postoperative BNP has the potential to show the 
preoperative condition of heart and cardiac injury 
induced by surgical intervention but its value as a 
prognostic marker has not been largely evaluated (7, 
8). 
Totonchi et al. evaluated the association of 
preoperative and post operative BNP with morbidity 
in 50 adult patients who were scheduled for elective 
CABG in Tehran Shahid Rajaie heart center from Sep 
2016 to May 2017. Patients with emergency 
situations, hematocrit less than 25 and patients on 
inotropic therapy were excluded. Samples were taken 
for BNP levels 24 hours pre and post operative. They 
showed that perioperative BNP did not have any 
correlation with other comorbidities and major 
complications after cardiac surgeries except for 
ejection fraction. Their results showed that patients 
with higher perioperative BNP levels had 
significantly higher risk factor for low ejection 
fraction and heat failure after CABG (9). Fox and 
coworkers in their prospective longitudinal study of 
1,183 patients undergoing primary coronary artery 
bypass grafting surgery, compared the utility of 
preoperative with postoperative BNP for predicting 
hospital LOS and mortality after primary PCI. After 
multivariable adjustment for preoperative BNP and 
clinical covariates, peak postoperative BNP predicted 
hospital LOS (hazard ratio [HR] = 1.28, 95% CI = 
1.002-1.64, P = 0.049) but not mortality. Whereas 
preoperative BNP independently predicted hospital 
LOS (HR = 1.09, CI = 1.01-1.18, P = 0.03) and was 
defined as an independent predictor of mortality 
(HR=1.36, CI=0.96-1.94, P=0.08). When 
preoperative and peak postoperative BNP were 
separately adjusted for the clinical multivariable 
models, each independently predicted hospital LOS 
and mortality (10). Previous studies showed that post 
operative BNP levels which measured 24 hours after 
surgery did not significantly predict adverse 
cardiovascular events and peak post operative BNP 
measurement should be considered as a surrogate for 
cardiovascular complications. Peak postoperative 
BNP tends to occur later in the postoperative course, 
around day 3 or 5. 
The study of Totonchi et al has some major 
limitations. It has been performed in a single center 
which has inherent limitations. The study’s HF 
outcome did not delineate specific etiologies of 
observed postoperative HF events (e.g., systolic vs. 
diastolic dysfunction or left atrial enlargement). BNP 
has been affected by kidney function and pulmonary 
disease but patients with kidney and lung disease 
were enrolled in this study. Moreover, the authors did 
not perform long term follow up after discharge. The 
authors measured BNP by electro-
chemiluminescence immunoassay, which measures 
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only nonglycoNT-proBNP. This method 
understimates the BNP level compared to NT-
proBNP assay system currently being used. 
Therefore, careful interpretation of the BNP levels 
and clinical application may be required. Finally, the 
authors did not use logistic regression analysis for 
adjustment of clinical risk factors; so, interpreting 
and globalization of these results is not possible. 
Based on literature review, there is little added 
benefit to measure postoperative BNP either instead of 
or in combination with preoperative BNP. So, it seems 
that we do not need to measure both preoperative and 
postoperative BNP together for the purposes of risk 
stratifying of CABG patients. But if preoperative BNP 
measurement is not possible, we can use peak post 
operative BNP measurement for prediction of major 
cardiovascular complications. Patients at high risk 
should be considered for less invasive procedures and 
must receive optimized perioperative care. Further 
research with a larger number of patients having 
various types of surgeries and good methodologic 
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